These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8366297)

  • 21. Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies.
    Bossuyt X
    Clin Chem Lab Med; 2000 Oct; 38(10):1033-7. PubMed ID: 11140619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (M85/F36) and its comparison with CA 15-3.
    Chu TM; Constantine R; Nemoto T
    J Clin Lab Anal; 1989; 3(5):267-72. PubMed ID: 2681619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A; Kessler AC
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the fully automated Cobas Core enzyme immunoassay for the quantitation of antibodies against hepatitis B virus surface antigen.
    Doche C; Thomé M; Dimet I; Bienvenu J
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):365-8. PubMed ID: 8704055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mucin-like carcinoma-associated antigen: sensitivity and specificity in metastatic breast cancer].
    Ammon A; Eiffert H; Alhusen R; Weber M; Rümelin B; Groh E; Bartsch H; Marschner N; Nagel GA; Krieger G
    Onkologie; 1990 Jun; 13(3):210-4. PubMed ID: 2204009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
    Gion M; Mione R; Gatti C; Dittadi R; Leon A; Nascimben O; Pizzorno B; Bruscagnin G
    Tumori; 1990 Aug; 76(4):360-4. PubMed ID: 2399565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
    Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
    Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating CA 549 and other associated antigens in breast cancer patients.
    Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
    Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antinuclear antibodies (ANA) screening by enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: analytical and clinical evaluation.
    González C; Guevara P; Alarcón I; Hernando M; Navajo JA; González-Buitrago JM
    Clin Biochem; 2002 Sep; 35(6):463-9. PubMed ID: 12413607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum markers for primary and recurrent breast cancer: BCM-EIA, CAM 26 and CAM 29.
    Ricketts D; Hadcocks L; Fitzek M; Rawson NS; Colston K; Powles TJ; Gazet JC; Coombes RC
    Tumour Biol; 1992; 13(4):207-16. PubMed ID: 1411139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
    Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
    Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simple method for comparing reliability of two serum tumour markers in breast carcinoma.
    O'Brien DP; Gough DB; Skehill R; Grimes H; Given HF
    J Clin Pathol; 1994 Feb; 47(2):134-7. PubMed ID: 8132827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.
    Laurence V; Forbes MA; Cooper EH
    Br J Cancer; 1991 Jun; 63(6):1000-4. PubMed ID: 2069833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
    Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA 549 as a marker in breast cancer.
    Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
    Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serum concentrations of the MCA tumor marker during pregnancy].
    Pütz I; Lang G; Winkler M; Rath W
    Zentralbl Gynakol; 1996; 118(7):409-11. PubMed ID: 8766103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of COBAS CORE anti-HIV-1/HIV-2 EIA DAGS for the detection of antibodies to HIV by COBAS CORE].
    Kodama T; Nada T; Yamamoto H; Morishita Y; Iinuma Y; Ichiyama S
    Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 1999; 10(1):43-50. PubMed ID: 10415449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
    Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M
    Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185
    [No Abstract]   [Full Text] [Related]  

  • 40. Measurement of CA 125 by an automated microparticle enzyme immunoassay; comparison with a manual enzyme immunoassay.
    Mogensen O; Mogensen B
    Scand J Clin Lab Invest; 1992 Oct; 52(6):507-12. PubMed ID: 1411262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.